BioSpace News Archive

Olympus Corporation announced it has signed a definitive agreement to acquire Arc Medical Design Limited, a subsidiary of Norgine B.V.

Freeline Therapeutics Holdings plc announced the pricing of its initial public offering in the United States of 8,823,529 American Depositary Shares representing 8,823,529 ordinary shares at an initial public offering price of $18.00 per ADS for total gross proceeds of approximately $158.8 million.

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with the Liverpool School of Tropical Medicine (“LSTM”) to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva.

--Completed all merger and integration activities in Q2-- --Repaid $10 million of Senior Secured Notes ahead of schedule-- --Zyla products partially contributed to Q2 net product sales of $20.2 million-- --Combined second quarter 2020 net product sales of $27.7 million, on a pro forma basis, increased modestly over pro forma first quarter 2020 despite COVID-19 and merger integration-- LAKE FOREST, Ill., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Com

Zomedica Pharmaceuticals Corp. (“Zomedica”) (NYSE American: ZOM), a veterinary health company, announced that Robert Cohen, Interim Chief Executive Officer, has been appointed to the Company’s Board of Directors. A

BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Friday, August 14, 2020 at 8:30 AM Eastern Time to discuss its second quarter 2020 operating and financial results. Conference Call & Webcast Details Date/Time: Fri

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. With this milestone, the data readout for the Day 28 immunogenicity endpoint remains on target for Q4 2020. The clinical trial has enrolled 42 evaluable healthy subjects to receive intranasally administered NasoShield or

• First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid Arthritis • First Subject Dosed in Phase 2a Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19 • Clinical Trial of ATI-1777, an Investigational “Soft” Topical JAK 1/3 Inhibitor, to Proceed in Patients with Moderate to Severe Atopic Dermatitis

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat at the 2020 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 11 at 10:20 a.m. ET. A live audio webcast of the presentation will be available here and on the Company’s website at www.arvina

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Dr. David Sans as Director, Corporate Development to be based in New York City. Dr. Sans will be responsible for planning and facilitation of XORTX corporate goals. Dr. Sans is an experienced pharmaceutical executive